BPA Levels Relationship With IVF/ICSI Outcomes in Patients With Male Factor

Impact of Blood and Ejaculate Bisphenol A Concentrations on ICSI Cycles Outcome in Patients With Male Factor

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05224284

Enrollment

Registered

2022-02-04

Start date

2019-05-01

Completion date

2019-10-30

Last updated

2022-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Male, IVF

Brief summary

Association between blood and semen BPA levels and ICSI outcomes in patients with male factor

Interventions

OTHERBPA levels

BPA (Bisfenol A) in blood and ejaculate samples

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

23 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* female patients aged 23-40 years who underwent IVF due to male factor * men with semen sample obtained from ejaculate * male patients provided blood, and ejaculate samples on the oocyte retrieval day * patients who did not smoke or use alcohol * patients did not work in the plastic industry

Exclusion criteria

* men with a diagnosis of azoospermia * patients who underwent IVF due to low ovarian reserve or unexplained infertility indications * patients diagnosed with endometriosis * patients with freeze-all cycles * women with metabolic disease (such as hypertension or diabetes mellitus) * patients (male or females) with a known genetic problem (male or female)

Design outcomes

Primary

Measure	Time frame	Description
Exposure to BPA	6 month	Concentrations of Bisphenol A (BPA) will be quantified in the blood plasma, and ejaculate (individual and pooled samples) by use of ELİSA test in women with male factor

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026